Gilead Built HIV Drug Empire On 'No Generic' Deals, Suit Says

By Jeff Overley · May 14, 2019, 9:50 PM EDT

Despite abysmal scientific innovation, Gilead Sciences Inc. constructed an HIV drug empire worth tens of billions of dollars by devising shadowy deals to block the use of lower-cost generics in combo...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Case Information

Case Title

In re HIV Antitrust Litigation

Case Number

Court

California Northern

Nature of Suit

Anti-Trust

Date Filed

May 14, 2019

Recent Articles By Jeff

June 29, 2024
Chevron's End Is Just The Start For Energized Agency Foes
June 17, 2024
Teva, DOJ Signal Key Kickback Case May Fizzle At 1st Circ.
March 29, 2024
Hogan Lovells Vet's High Court Debut A Study In Contrasts
January 29, 2024
The Top Attys In Clinton's Impeachment Trial, 25 Years Later
January 18, 2024
'Chaos' Warning Resonates As Justices Mull Chevron's Fate
January 01, 2024
Appellate Outlook: Circuit Splits & Hot Topics To Track In 2024
December 09, 2023
Circuit-By-Circuit Guide To 2023's Most Memorable Moments
November 09, 2023
Paul Clement's Big Idea: Overrule Chevron, Ease Polarization
October 27, 2023
Are Justices Split 3-3-3? New Term Is Already Offering Clues
October 18, 2023
Novartis Airs Mea Culpa As 2nd Circ. Probes Kickback Theory